Cite
HARVARD Citation
Andrieux-Meyer, I. et al. (2021). Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet gastroenterology and hepatology. pp. 448-458. [Online].